Product Description
Mechanisms of Action: ERBB3 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: DualityBio
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Breast Cancer|Esophageal Cancer|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Prostate Cancer|Squamous Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
DB-1310-O-1001 | P2 |
Recruiting |
Prostate Cancer|Esophageal Cancer|Non-Small-Cell Lung Cancer|Breast Cancer|Head and Neck Cancer|Squamous Cell Carcinoma |
2026-08-31 |